Lichen planus - Pipeline Insight, 2021
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Lichen planus – Pipeline Insight, 2021,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Lichen planus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Lichen planus: Overview
Lichen planus is a T cell-mediated autoimmune disorder, in which inflammatory cells attack an unknown protein within the skin and mucosal keratinocytes. There are several clinical types of lichen planus that share similar features on histopathology. Lichen planus affects about one in one hundred people worldwide, mostly affecting adults over the age of 40 years. About half those affected have oral lichen planus, which is more common in women than in men. About 10% have lichen planus of the nails. Symptoms of lichen planus depend on the part or parts of your body affected. The most common symptoms are shiny red or purple bumps on skin. Lichen planus inside mouth looks like lacy patches of tiny white dots. Lichen planus may appear on a few, or all, of your fingernails and toenails. Thinning, ridges, splitting, and nail loss are signs of the condition. To make sure of the diagnosis, the doctor will perform a biopsy. He or she will remove mouth mucosa, or a small piece of skin, and send it to be examined it under a microscope. Lichen planus has no cure, but different treatments can help relieve symptoms and speed healing.
'Lichen planus - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lichen planus pipeline landscape is provided which includes the disease overview and Lichen planus treatment guidelines. The assessment part of the report embraces, in depth Lichen planus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lichen planus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Lichen planus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Lichen planus Emerging Drugs
Further product details are provided in the report……..
Lichen planus: Therapeutic Assessment
This segment of the report provides insights about the different Lichen planus drugs segregated based on following parameters that define the scope of the report, such as:
Lichen planus: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lichen planus therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lichen planus drugs.
Lichen planus Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Lichen planus – Pipeline Insight, 2021,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Lichen planus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Lichen planus: Overview
Lichen planus is a T cell-mediated autoimmune disorder, in which inflammatory cells attack an unknown protein within the skin and mucosal keratinocytes. There are several clinical types of lichen planus that share similar features on histopathology. Lichen planus affects about one in one hundred people worldwide, mostly affecting adults over the age of 40 years. About half those affected have oral lichen planus, which is more common in women than in men. About 10% have lichen planus of the nails. Symptoms of lichen planus depend on the part or parts of your body affected. The most common symptoms are shiny red or purple bumps on skin. Lichen planus inside mouth looks like lacy patches of tiny white dots. Lichen planus may appear on a few, or all, of your fingernails and toenails. Thinning, ridges, splitting, and nail loss are signs of the condition. To make sure of the diagnosis, the doctor will perform a biopsy. He or she will remove mouth mucosa, or a small piece of skin, and send it to be examined it under a microscope. Lichen planus has no cure, but different treatments can help relieve symptoms and speed healing.
'Lichen planus - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lichen planus pipeline landscape is provided which includes the disease overview and Lichen planus treatment guidelines. The assessment part of the report embraces, in depth Lichen planus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lichen planus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Lichen planus R&D. The therapies under development are focused on novel approaches to treat/improve Lichen planus.
This segment of the Lichen planus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Lichen planus Emerging Drugs
- Rivelin-CLO: AFYX Therapeutics
Further product details are provided in the report……..
Lichen planus: Therapeutic Assessment
This segment of the report provides insights about the different Lichen planus drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Lichen planus
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Lichen planus: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lichen planus therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lichen planus drugs.
Lichen planus Report Insights
- Lichen planus Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Lichen planus drugs?
- How many Lichen planus drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lichen planus?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Lichen planus therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Lichen planus and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Lichen planus: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Rivelin-CLO: AFYX Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
Comparative Analysis
LP-310: Lipella Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Lichen planus Key Companies
Lichen planus Key Products
Lichen planus- Unmet Needs
Lichen planus- Market Drivers and Barriers
Lichen planus- Future Perspectives and Conclusion
Lichen planus Analyst Views
Lichen planus Key Companies
Appendix
Executive Summary
Lichen planus: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Rivelin-CLO: AFYX Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
Comparative Analysis
LP-310: Lipella Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Lichen planus Key Companies
Lichen planus Key Products
Lichen planus- Unmet Needs
Lichen planus- Market Drivers and Barriers
Lichen planus- Future Perspectives and Conclusion
Lichen planus Analyst Views
Lichen planus Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Lichen planus
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Lichen planus
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Lichen planus
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Lichen planus
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
